Breaking News Instant updates and real-time market news.

NVS

Novartis

$75.68

0.13 (0.17%)

05:41
03/21/17
03/21
05:41
03/21/17
05:41

Novartis says Cosentyx may modify course of moderate-to- severe psoriasis

Novartis announced new data suggesting, for the first time, that Cosentyx may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance. Cosentyx is the first and only IL-17A inhibitor to have reported this potential of disease modification. These data were presented at the 13th Annual Maui Derm for Dermatologists 2017, Maui, Hawaii at which Novartis presented 14 abstracts. Following one year of treatment with Cosentyx, patients were randomized to either continuous treatment or treatment cessation until relapse. Patients with continuous treatment maintained their high level of response. Among the patients that discontinued treatment, 21% of psoriasis patients maintained skin clearance for up to one year without treatment and 10% maintained skin clearance after two years without treatment. Patients with longer disease duration were more likely to relapse, suggesting that early intervention increases the chance of remaining relapse free.

  • 26

    Jun

NVS Novartis
$75.68

0.13 (0.17%)

03/07/17
SOCG
03/07/17
UPGRADE
SOCG
Buy
Novartis upgraded to Buy from Hold at Societe Generale
03/07/17
LEHM
03/07/17
INITIATION
LEHM
Underweight
Novartis reinstated with an Underweight at Barclays
Barclays analyst Emmanuel Papadakis reinstated Novo Nordisk with an Underweight rating.
03/07/17
LEHM
03/07/17
NO CHANGE
LEHM
European Pharma raised to Positive from Neutral at Barclays
Barclays analyst Emmanuel Papadakis rolled out coverage of the European Pharmaceuticals space and upgraded his sector view to Positive from Neutral. The analyst has "high conviction that the recent transformational era of R&D innovation is set to continue," which he believes will allow the sector to retain pricing power. Papadakis put Overweight ratings on AstraZeneca (AZN), Roche (RHHBY) and Shire (SHPG), with Astra his top pick. The analyst put an Equal Weight rating on GlaxoSmithKline (GSK) and Underweight ratings on Sanofi (SNY), Novartis (NVS) and Novo Nordisk (NVO).
03/14/17
LEER
03/14/17
NO CHANGE
LEER
Monitoring requests put Novartis Kisqali at marketing disadvantage, says Leerink
Leerink analyst Seamus Fernandez notes that Novartis (NVS) announced the FDA approval of its CDK4/6 inhibitor Kisqali in combination with an aromatase inhibitor for the first-line treatment of post-menopausal women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. The analyst says that the label contains warnings for QT prolongation as well as liver toxicity, both of which necessitate frequent monitoring. Although Kisqali appears to have similar efficacy to Pfizer (PFE) approved Ibrance, the latter's label does not include these warnings or monitoring requirements, he points out, adding that he continues to see Ibrance maintaining long-term market dominance in the CDK4/6 class.

TODAY'S FREE FLY STORIES

BDGE

Bridge Bancorp

$32.90

-0.7 (-2.08%)

16:32
07/26/17
07/26
16:32
07/26/17
16:32
Earnings
Breaking Earnings news story on Bridge Bancorp »

Bridge Bancorp reports Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

QEP

QEP Resources

$9.27

0.07 (0.76%)

16:31
07/26/17
07/26
16:31
07/26/17
16:31
Earnings
QEP Resources reports Q2 adjusted EPS (12c), consensus (20c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

MPWR

Monolithic Power

$106.79

1.86 (1.77%)

16:31
07/26/17
07/26
16:31
07/26/17
16:31
Earnings
Breaking Earnings news story on Monolithic Power »

Monolithic Power sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 08

    Aug

  • 10

    Aug

  • 15

    Aug

UDR

UDR, Inc.

$39.19

0.51 (1.32%)

16:31
07/26/17
07/26
16:31
07/26/17
16:31
Earnings
UDR, Inc. backs FY17 EPS view of 31c-36c, consensus 28c »

Reaffirmed FFO per share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

FFIV

F5 Networks

$128.20

0.18 (0.14%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
F5 Networks sees Q4 non-GAAP EPS $2.20-$2.23, consensus $2.24 »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 05

    Sep

MPWR

Monolithic Power

$106.79

1.86 (1.77%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
Monolithic Power reports Q2 EPS 68c, consensus 67c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 08

    Aug

  • 10

    Aug

  • 15

    Aug

O

Realty Income

$57.92

0.49 (0.85%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
Realty Income reports Q2 EPS 30c, consensus 32c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

FMNB

Farmers National Banc

$14.35

-0.4 (-2.71%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
Farmers National Banc reports Q2 EPS 21c, consensus 22c »

Total loans were $1.51…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRCY

Mercury Systems

$43.86

-0.13 (-0.30%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Hot Stocks
Mercury Systems receives $5.5M order »

Mercury Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 07

    Aug

ESND

Essendant

$13.41

-0.42 (-3.04%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
Essendant sees FY17 sales decline of 6%-9%, consensus $5.22B »

Management said, "In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Options
Preliminary option volume of 17.4M today »

Preliminary option volume…

NTRI

Nutrisystem

$62.95

1.3 (2.11%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Hot Stocks
Breaking Hot Stocks news story on Nutrisystem »

Nutrisystem trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

UDR

UDR, Inc.

$39.19

0.51 (1.32%)

16:29
07/26/17
07/26
16:29
07/26/17
16:29
Earnings
UDR, Inc. reports Q2 AFFO 43c vs. 41c last year »

UDR reports Q2 Funds from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

FFIV

F5 Networks

$128.20

0.18 (0.14%)

16:29
07/26/17
07/26
16:29
07/26/17
16:29
Earnings
F5 Networks reports Q3 non-GAAP EPS $2.03, consensus $2.03 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 05

    Sep

FORR

Forrester

$41.60

0.15 (0.36%)

16:29
07/26/17
07/26
16:29
07/26/17
16:29
Earnings
Forrester sees FY17 pro forma EPS $1.13-$1.20, consensus $1.17 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

BAC

Bank of America

$24.21

-0.27 (-1.10%)

, PYPL

PayPal

$58.79

0.53 (0.91%)

16:29
07/26/17
07/26
16:29
07/26/17
16:29
Hot Stocks
PayPal, BofA partner to enable in-store payments and account linking »

Bank of America (BAC) and…

BAC

Bank of America

$24.21

-0.27 (-1.10%)

PYPL

PayPal

$58.79

0.53 (0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 09

    Aug

  • 10

    Aug

AXTI

AXT, Inc.

$7.60

0.25 (3.40%)

16:28
07/26/17
07/26
16:28
07/26/17
16:28
Earnings
AXT, Inc. reports Q2 EPS 5c, consensus 5c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 03

    Aug

  • 10

    Aug

  • 19

    Sep

UDR

UDR, Inc.

$39.19

0.51 (1.32%)

16:28
07/26/17
07/26
16:28
07/26/17
16:28
Earnings
UDR, Inc. reports Q2 EPS 3c, consensus 6c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

ESND

Essendant

$13.41

-0.42 (-3.04%)

16:28
07/26/17
07/26
16:28
07/26/17
16:28
Earnings
Essendant reports Q2 adjusted EPS 28c, consensus 37c »

Reports Q2 revenue $1.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

KS

KapStone

$22.52

-0.17 (-0.75%)

16:28
07/26/17
07/26
16:28
07/26/17
16:28
Earnings
KapStone reports Q2 adjusted EPS 27c, consensus 27c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

FORR

Forrester

$41.60

0.15 (0.36%)

16:28
07/26/17
07/26
16:28
07/26/17
16:28
Earnings
Forrester sees Q3 pro forma EPS 21c-25c, consensus 26c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

AHL

Aspen Insurance

$51.00

-0.75 (-1.45%)

16:27
07/26/17
07/26
16:27
07/26/17
16:27
Earnings
Aspen Insurance reports Q2 ops EPS 47c, consensus $1.00 »

Chris O'Kane, Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

OKE

Oneok

$55.59

-0.19 (-0.34%)

16:27
07/26/17
07/26
16:27
07/26/17
16:27
Hot Stocks
Oneok raises quarterly dividend 21% to 74.5c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

MB

Mindbody

$26.10

-0.05 (-0.19%)

16:27
07/26/17
07/26
16:27
07/26/17
16:27
Earnings
Breaking Earnings news story on Mindbody »

Mindbody sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

TYL

Tyler Technologies

$181.33

0.32 (0.18%)

16:27
07/26/17
07/26
16:27
07/26/17
16:27
Earnings
Tyler Technologies sees FY17 EPS $3.83-$3.91, consensus $3.88 »

Sees FY17 GAAP revenues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

  • 05

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.